Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.76
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
October 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
October 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Perfumes Of Arabia
October 06, 2021
Downtrends do eventually run out of pessimistic steam, but it can take a while.
Via
Talk Markets
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
Upgrades For State Street Corporation (NYSE:
Via
Benzinga
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
October 06, 2021
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 06, 2021
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a...
Via
Benzinga
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
October 06, 2021
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the...
Via
Benzinga
Takeda Stock Nears Two-Year Low After This Issue Shuttered Two Narcolepsy Tests
October 06, 2021
Takeda Pharmaceutical was testing a drug called TAK-994 in narcolepsy patients.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 06, 2021
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9...
Via
Benzinga
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
October 06, 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin...
Via
Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
Takeda Provides Update on TAK-994 Clinical Program
October 05, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines
October 01, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA...
Via
Benzinga
Exposures
COVID-19
September Ends
September 30, 2021
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling.
Via
Talk Markets
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Takeda In-Licenses Hunter Syndrome Candidate
September 30, 2021
Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to...
Via
Benzinga
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
September 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
September 24, 2021
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in...
Via
Benzinga
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
September 22, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
September 21, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
September 21, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...
Via
Benzinga
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
September 16, 2021
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for...
Via
Benzinga
Exposures
Product Safety
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
September 15, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.